[e-mail]

Create Your Own Diagnostics ETF

Mike, about 99.99% of amag valuation is a drug, not an imaging agent.

AMAG's Iron Replacement Therapy: Great Potential, Problematic Trial

Reza, that's just one amag phase III trial of many. They didn't submit with just those 31 patients, they submitted with something like 1700 patients. Also keep in mind that trial was in patients having undergone kidney *transplants* with continuing CKD. Which isn't exactly a place you can easily run out and find 500 patients or their primary market.

JM